Literature DB >> 32029130

A Contemporary Picture of Enterococcal Endocarditis.

Juan M Pericàs1, Jaume Llopis2, Patricia Muñoz3, Juan Gálvez-Acebal4, Martha Kestler3, Maricela Valerio3, Marta Hernández-Meneses5, Miguel Á Goenaga6, Manuel Cobo-Belaustegui7, Miguel Montejo8, Guillermo Ojeda-Burgos9, M Dolores Sousa-Regueiro10, Arístides de Alarcón11, Antonio Ramos-Martínez12, José M Miró13.   

Abstract

BACKGROUND: Enterococcal endocarditis (EE) is a growing entity in Western countries. However, quality data from large studies is lacking.
OBJECTIVES: The purpose of this study was to describe the characteristics and analyze the prognostic factors of EE in the GAMES cohort.
METHODS: This was a post hoc analysis of a prospectively collected cohort of patients from 35 Spanish centers from 2008 to 2016. Characteristics and outcomes of 516 cases of EE were compared with those of 3,308 cases of nonenterococcal endocarditis (NEE). Logistic regression and Cox proportional hazards regression analysis were performed to investigate risk factors for in-hospital and 1-year mortality, as well as relapses.
RESULTS: Patients with EE were significantly older; more frequently presented chronic lung disease, chronic heart failure, prior endocarditis, and degenerative valve disease; and had higher median age-adjusted Charlson score. EE more frequently involved the aortic valve and prosthesis (64.3% vs. 46.7%; p < 0.001; and 35.9% vs. 28.9%; p = 0.002, respectively) but less frequently pacemakers/defibrillators (1.5% vs. 10.5%; p < 0.001), and showed higher rates of acute heart failure (45% vs. 38.3%; p = 0.005). Cardiac surgery was less frequently performed in EE (40.7% vs. 45.9%; p = 0.024). No differences in in-hospital and 1-year mortality were found, whereas relapses were significantly higher in EE (3.5% vs. 1.7%; p = 0.035). Increasing Charlson score, LogEuroSCORE, acute heart failure, septic shock, and paravalvular complications were risk factors for mortality, whereas prior endocarditis was protective and persistent bacteremia constituted the sole risk factor for relapse.
CONCLUSIONS: Besides other baseline and clinical differences, EE more frequently affects prosthetic valves and less frequently pacemakers/defibrillators. EE presents higher rates of relapse than NEE.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  enterococci; epidemiology; heart failure; infective endocarditis; prosthetic valves; relapses

Mesh:

Year:  2020        PMID: 32029130     DOI: 10.1016/j.jacc.2019.11.047

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

Authors:  Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  The year in cardiovascular medicine 2020: valvular heart disease.

Authors:  Javier Bermejo; Andrea Postigo; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2021-02-11       Impact factor: 29.983

3.  Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT.

Authors:  Laura Herrera-Hidalgo; Jose Manuel Lomas-Cabezas; Luis Eduardo López-Cortés; Rafael Luque-Márquez; Luis Fernando López-Cortés; Francisco J Martínez-Marcos; Javier de la Torre-Lima; Antonio Plata-Ciézar; Carmen Hidalgo-Tenorio; Maria Victoria García-López; David Vinuesa; Alicia Gutiérrez-Valencia; Maria Victoria Gil-Navarro; Arístides De Alarcón
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

4.  Clinical and microbiological characteristics of bloodstream infections caused by Enterococcus spp. within internal medicine wards: a two-year single-centre experience.

Authors:  Tommaso Lupia; Gianmario Roberto; Luca Scaglione; Nour Shbaklo; Ilaria De Benedetto; Silvia Scabini; Simone Mornese Pinna; Antonio Curtoni; Rossana Cavallo; Francesco Giuseppe De Rosa; Silvia Corcione
Journal:  Intern Emerg Med       Date:  2022-01-29       Impact factor: 5.472

5.  Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score-Matched, Retrospective Cohort Analysis.

Authors:  Niyati H Shah; Kathleen A Shutt; Yohei Doi
Journal:  Open Forum Infect Dis       Date:  2021-03-06       Impact factor: 3.835

6.  Relationship among Streptococcus gallolyticus Subsp. gallolyticus, Enterococcus faecalis and Colorectal Neoplasms in Recurrent Endocarditis: A Historical Case Series.

Authors:  Eva Romay; Juan Manuel Pericàs; María José García-País; Marta Hernández-Meneses; Blanca Ayuso; Javier García-González; Rodrigo Vicente Garcés-Durán; Ramón Rabuñal; Pilar Alonso-García; Fernando García-Garrote; Andrés Perissinotti; Bàrbara Vidal; Carles Falces; Eduard Quintana; Leticia Moreira; Manel Almela; Josep Llach; Asunción Moreno; Juan Corredoira; Jose María Miró
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.241

7.  Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates.

Authors:  Jaclyn A Cusumano; Ruhma Khan; Zeel Shah; Cassie Philogene; Amrita Harrichand; Vanthida Huang
Journal:  Microbiol Spectr       Date:  2022-06-15

8.  A retrospective study of Enterococcus faecalis infective endocarditis: comparison of clinical characteristics and outcomes associated with treatment.

Authors:  N Vigneswaran; G McKew
Journal:  JAC Antimicrob Resist       Date:  2022-09-30

9.  Outcomes and Risk Factors of Septic Shock in Patients With Infective Endocarditis: A Prospective Cohort Study.

Authors:  Juan M Pericàs; Marta Hernández-Meneses; Patricia Muñoz; Ana Álvarez-Uría; Blanca Pinilla-Llorente; Arístides de Alarcón; Karlos Reviejo; M Carmen Fariñas; Carlos Falces; Josune Goikoetxea-Agirre; Juan Gálvez-Acebal; Carmen Hidalgo-Tenorio; Eloy Gómez-Nebreda; Jose M Miro
Journal:  Open Forum Infect Dis       Date:  2021-03-25       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.